Search Results - Andrea Wang‐Gillam

Refine Results
  1. 1
    Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

    Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies by Andrea S. Teague, Kian‐Huat Lim, Andrea Wang‐Gillam

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Targeting RAS -mutant Cancers: Is ERK the Key?

    Targeting RAS -mutant Cancers: Is ERK the Key? by Meagan B. Ryan, Channing J. Der, Andrea Wang‐Gillam, Adrienne D. Cox

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome

    Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome by Joan How, Margaret Blattner, Susan A. Fowler, Andrea Wang‐Gillam, Suzanne E. Schindler

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study

    Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study by Katrina S. Pedersen, George P. Kim, Nathan R. Foster, Andrea Wang‐Gillam, Charles Erlichman, Robert R. McWilliams

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?

    Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm? by Kian‐Huat Lim, Eugene H. Chung, Adeel S. Khan, Dengfeng Cao, David C. Linehan, Edgar Ben‐Josef, Andrea Wang‐Gillam

    Published 2012
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

    NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors by Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke, Daniel D. Von Hoff, Bruce Belanger, Floris A. de Jong, Beloo Mirakhur, Li‐Tzong Chen

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer

    Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer by Daoxiang Zhang, Lin Li, Hongmei Jiang, Qiong Li, Andrea Wang‐Gillam, Jinsheng Yu, Richard Head, Jingxia Liu, Marianna B. Ruzinova, Kian‐Huat Lim

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models

    Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models by Hongmei Jiang, Ming Xu, Lin Li, Patrick Grierson, Paarth B. Dodhiawala, Maureen Highkin, Daoxiang Zhang, Qiong Li, Andrea Wang‐Gillam, Kian‐Huat Lim

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer

    Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer by Peter S. Goedegebuure, Jonathan B. Mitchem, Matthew R. Porembka, Marcus Tan, Brian A. Belt, Andrea Wang‐Gillam, William E. Gillanders, William G. Hawkins, David C. Linehan

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma

    Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma by Daoxiang Zhang, Lin Li, Hongmei Jiang, Brett L. Knolhoff, A. Craig Lockhart, Andrea Wang‐Gillam, David G. DeNardo, Marianna B. Ruzinova, Kian‐Huat Lim

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer

    Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer by Xiaofei Zhou, Xiaoyan Yang, Boris Grinshpun, Adekemi Taylor, Laura E. Strong, Arvind Dasari, Andrea Wang‐Gillam, Jin Li, Rui‐Hua Xu, Neeraj Gupta, Caly Chien

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

    CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models by Yu Zhu, Brett L. Knolhoff, Melissa A. Meyer, Timothy M. Nywening, Brian L. West, Jingqin Luo, Andrea Wang‐Gillam, S. Peter Goedegebuure, David C. Linehan, David G. DeNardo

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation

    Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation by Comron Hassanzadeh, Soumon Rudra, A. Bommireddy, William G. Hawkins, Andrea Wang‐Gillam, Ryan C. Fields, Bin Cai, Justin Park, Olga Green, Michael Roach, Lauren E. Henke, Hyun Kim

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors

    A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tum... by Manik Amin, Susan Minton, Patricia LoRusso, Smitha Krishnamurthi, Cheryl A. Pickett, Jared Lunceford, Darcy A. Hille, David Mauro, Mark N. Stein, Andrea Wang‐Gillam, Lauren Trull, A. Craig Lockhart

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

    CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocar... by L-T. Chen, Andrea Wang‐Gillam, Y-S Shan, T. Macarulla Mercadé, Jan Blanc, Richard Hubner, C-F. Chiu, G. Schwartsmann, J. Siveke, Bruce Belanger, F. de Jong, K. Mamlouk, D. Von Hoff

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

    A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma by Andrea Wang‐Gillam, Stacey M. Plambeck-Suess, Peter S. Goedegebuure, Peter O. Simon, Jonathan B. Mitchem, John R. Hornick, Steven Sorscher, Joel Picus, Rama Suresh, A. Craig Lockhart, Benjamin Tan, W. Hawkins

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

    Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors by Mark H. O’Hara, Wells A. Messersmith, Hedy L. Kindler, Wei Zhang, Celine Pitou, Anna M. Szpurka, Dan Wang, Sheng-Bin Peng, Burkhard Vangerow, Anis A. Khan, Mythili Koneru, Andrea Wang‐Gillam

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Surgical Outcome Results From SWOG S1505

    Surgical Outcome Results From SWOG S1505 by Syed A. Ahmad, Mai Duong, Davendra Sohal, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James L. Wade, E. Gabriela Chiorean, Katherine A. Guthrie, Andrew M. Lowy, Philip A. Philip, Howard S. Höchster

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

    Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma by Davendra Sohal, Mai Duong, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James L. Wade, E. Gabriela Chiorean, Katherine A. Guthrie, Andrew M. Lowy, Philip A. Philip, Howard S. Höchster

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

    Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma by Patrick Grierson, Benjamin Tan, Katrina S. Pedersen, Haeseong Park, Rama Suresh, Manik Amin, Nikolaos A. Trikalinos, Deborah Knoerzer, Brent Kreider, Anupama Reddy, Jingxia Liu, Channing J. Der, Andrea Wang‐Gillam, Kian‐Huat Lim

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: